RVL Pharmaceuticals PLC reports results for the quarter ended in June - Earnings Summary

RVL Pharmaceuticals

11/08/2022 14:33

* RVL Pharmaceuticals PLC  RVLP.OQ  reported a quarterly
adjusted
loss of 14 cents​​ per share for the quarter ended in June. The
mean expectation of four analysts for the quarter was for a loss
of 21 cents per share.
    * Revenue fell 26.6% to $8.45 million from a year ago;
analysts
expected $8.52 million. 
    * RVL Pharmaceuticals PLC's reported EPS for the quarter was
a
loss of 14 cents​.
    * The mean earnings estimate of analysts had fallen by
about 26.5%
in the last three months.​ 
    * In the last 30 days two analysts negatively revised
earnings
estimates 
    * RVL Pharmaceuticals PLC shares had risen by 37.9% this
quarter and gained 73.6% so far this year.
    * The company reported a quarterly loss of $12.11 million.
    * Wall Street's median 12-month price target for RVL
Pharmaceuticals PLC is $4.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 11
at 01:32 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.21          -0.14          Beat
 Mar. 31 2022      -0.17          -0.25          Missed
 Dec. 31 2021      -0.27          -0.30          Missed
 Sep. 30 2021      -0.31          -0.28          Beat